Literature DB >> 23797673

Macrophage migration inhibitory factor potentiates autoimmune-mediated neuroinflammation.

Gina Mavrikis Cox1, Aaron P Kithcart, David Pitt, Zhen Guan, Jessica Alexander, Jessica L Williams, Todd Shawler, Nilesh M Dagia, Phillip G Popovich, Abhay R Satoskar, Caroline C Whitacre.   

Abstract

Macrophage migration inhibitory factor (MIF) is a multipotent cytokine that is associated with clinical worsening and relapses in multiple sclerosis (MS) patients. The mechanism through which MIF promotes MS progression remains undefined. In this study, we identify a critical role for MIF in regulating CNS effector mechanisms necessary for the development of inflammatory pathology in a mouse model of MS, experimental autoimmune encephalomyelitis (EAE). Despite the ability to generate pathogenic myelin-specific immune responses peripherally, MIF-deficient mice have reduced EAE severity and exhibit less CNS inflammatory pathology, with a greater percentage of resting microglia and fewer infiltrating inflammatory macrophages. We demonstrate that MIF is essential for promoting microglial activation and production of the innate soluble mediators IL-1β, IL-6, TNF-α, and inducible NO synthase. We propose a novel role for MIF in inducing microglial C/EBP-β, a transcription factor shown to regulate myeloid cell function and play an important role in neuroinflammation. Intraspinal stereotaxic microinjection of MIF resulted in upregulation of inflammatory mediators in microglia, which was sufficient to restore EAE-mediated inflammatory pathology in MIF-deficient mice. To further implicate a role for MIF, we show that MIF is highly expressed in human active MS lesions. Thus, these results illustrate the ability of MIF to influence the CNS cellular and molecular inflammatory milieu during EAE and point to the therapeutic potential of targeting MIF in MS.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23797673     DOI: 10.4049/jimmunol.1200485

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  37 in total

1.  HLA-DRα1 constructs block CD74 expression and MIF effects in experimental autoimmune encephalomyelitis.

Authors:  Roberto Meza-Romero; Gil Benedek; Xiaolin Yu; Jeffery L Mooney; Rony Dahan; Nerri Duvshani; Richard Bucala; Halina Offner; Yoram Reiter; Gregory G Burrows; Arthur A Vandenbark
Journal:  J Immunol       Date:  2014-03-28       Impact factor: 5.422

Review 2.  A Blazing Landscape: Neuroinflammation Shapes Brain Metastasis.

Authors:  Hila Doron; Tobias Pukrop; Neta Erez
Journal:  Cancer Res       Date:  2019-01-24       Impact factor: 12.701

Review 3.  Can we switch microglia's phenotype to foster neuroprotection? Focus on multiple sclerosis.

Authors:  Debora Giunti; Benedetta Parodi; Christian Cordano; Antonio Uccelli; Nicole Kerlero de Rosbo
Journal:  Immunology       Date:  2014-03       Impact factor: 7.397

4.  MIF and D-DT are potential disease severity modifiers in male MS subjects.

Authors:  Gil Benedek; Roberto Meza-Romero; Kelley Jordan; Ying Zhang; Ha Nguyen; Gail Kent; Jia Li; Edwin Siu; Jenny Frazer; Marta Piecychna; Xin Du; Antoine Sreih; Lin Leng; Jack Wiedrick; Stacy J Caillier; Halina Offner; Jorge R Oksenberg; Vijayshree Yadav; Dennis Bourdette; Richard Bucala; Arthur A Vandenbark
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-18       Impact factor: 11.205

Review 5.  Partial MHC class II constructs as novel immunomodulatory therapy for stroke.

Authors:  Gil Benedek; Arthur A Vandenbark; Nabil J Alkayed; Halina Offner
Journal:  Neurochem Int       Date:  2016-10-31       Impact factor: 3.921

6.  Predicted structure of MIF/CD74 and RTL1000/CD74 complexes.

Authors:  Roberto Meza-Romero; Gil Benedek; Lin Leng; Richard Bucala; Arthur A Vandenbark
Journal:  Metab Brain Dis       Date:  2016-02-06       Impact factor: 3.584

7.  Kv1.3 channel-blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseases.

Authors:  Sandeep Chhabra; Shih Chieh Chang; Hai M Nguyen; Redwan Huq; Mark R Tanner; Luz M Londono; Rosendo Estrada; Vikas Dhawan; Satendra Chauhan; Sanjeev K Upadhyay; Mariel Gindin; Peter J Hotez; Jesus G Valenzuela; Biswaranjan Mohanty; James D Swarbrick; Heike Wulff; Shawn P Iadonato; George A Gutman; Christine Beeton; Michael W Pennington; Raymond S Norton; K George Chandy
Journal:  FASEB J       Date:  2014-06-02       Impact factor: 5.191

Review 8.  Macrophages: a double-edged sword in experimental autoimmune encephalomyelitis.

Authors:  Zhilong Jiang; Jack X Jiang; Guang-Xian Zhang
Journal:  Immunol Lett       Date:  2014-03-31       Impact factor: 3.685

9.  Brief report: Enhanced DRα1-mMOG-35-55 treatment of severe EAE in MIF-1-deficient male mice.

Authors:  Arthur A Vandenbark; Roberto Meza-Romero; Jack Wiedrick; Grant Gerstner; Ashley Headrick; Gail Kent; Hilary Seifert; Gil Benedek; Richard Bucala; Halina Offner
Journal:  Cell Immunol       Date:  2021-09-11       Impact factor: 4.868

10.  D-dopachrome tautomerase activates COX2/PGE2 pathway of astrocytes to mediate inflammation following spinal cord injury.

Authors:  Huiyuan Ji; Yuxin Zhang; Chen Chen; Hui Li; Bingqiang He; Ting Yang; Chunshuai Sun; Huifei Hao; Xingyuan Zhang; Yingjie Wang; Yue Zhou; Zhenjie Zhu; Yuming Hu; Aihong Li; Aisong Guo; Yongjun Wang
Journal:  J Neuroinflammation       Date:  2021-06-11       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.